An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
Novartis Pharmaceuticals
Summary
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Description
This is an open-label, multi-center, global roll-over study designed to assess long term safety and provide continued treatment to participants who have previously participated in an asciminib Novartis sponsored study and who, in the opinion of the investigator, would benefit from continued treatment as in their parent study but are unable to access this treatment outside of the clinical study.
Eligibility
- Age range
- 7–100 years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria: 1. Participant with PH+ CML or PH+ ALL currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasatinib), imatinib, nilotinib or bosutinib alone within a Novartis-sponsored study and, in the opinion of the Investigator, would benefit from continued treatment. 2. Participant has demonstrated compliance on the parent study protocol and is willing and able to comply with scheduled visits, treatment plans and any other study procedures. Key Exclusion Criteria: 1. Participant has been discontinued from parent study treatme…
Interventions
- DrugAsciminib single agent
Taken orally, twice daily (BID) or once daily (QD), in fasting state
- DrugImatinib
Taken orally, once daily, in the morning with low-fat meal
- DrugNilotinib
Taken orally, twice daily, on an empty stomach
- DrugBosutinib
Taken orally, once daily, with food
- DrugDasatinib
Taken orally, once daily in a fasted state, 1 or 2 hours before a meal
- DrugAsciminib single agent pediatric formulation
Pediatric participants receive a body weight adjusted dose of 1.3 mg/kg of pediatric film coated granules with food twice daily (b.i.d.) or 2.6 mg/kg once daily (q.d.) in the morning.
Locations (84)
- Michigan Med University of MichiganAnn Arbor, Michigan
- Memorial Sloan KetteringNew York, New York
- Oregon Health Sciences UniversityPortland, Oregon
- Texas OncologyDallas, Texas
- Uni Of TX MD Anderson Cancer CntrHouston, Texas
- Novartis Investigative SiteCABA, Buenos Aires